Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Status:
Active, not recruiting
Trial end date:
2022-02-07
Target enrollment:
Participant gender:
Summary
The aim of the research in this study is to make participants' transplant safer by reducing
the risk of developing GVHD and GVHD-related complications by giving participants a dose of
the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab
reduces the risk of inflammation by blocking the effect of Interleukin-6, a protein that
exists in high levels in the blood when there is inflammation. Participants who receive stem
cell transplants have high levels of this protein in their blood early after transplant.
Therefore, the goal of this study is to reduce the risk of inflammation after transplant with
the addition of Tocilizumab. This could decrease the risk of developing GVHD and
GVHD-associated complications.